Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Breast 1

Conditions

Overweight 1Obesity 1Breast Neoplasms 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Has results × bupropion hydrochloride, naltrexone hydrochoride drug combination × Clear all
NCT04499950 2025-03-06

A-NEW

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
53 enrolled 14 charts
BreastOther

Breast Neoplasms, Obesity, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡